The Government is considering whether to move from the gender-specific language of cancer treatment to one that does not.
The move would give women the same access to cancer treatment as men, and would ensure the NHS and cancer charities can cater for them as well as their male counterparts.
The Gender Recognition Act 2016 will be brought forward from the beginning of the next Parliament and the Government will discuss it on Monday.
A spokesman for Health Minister Simon Harris said it was important to protect the NHS.
“Women are at higher risk of cancers, particularly cancer of the breast and prostate, than men.
We know that men’s cancers are more aggressive, they have a higher survival rate, and that this is a key factor in the increased risk of dying from cancer.”
The Gender Reconciliation Act 2016 provides for a new gender recognition language to be used for cancer treatment.
“We recognise that this will mean that, in order to be treated, women will have to undergo gender reassignment surgery, which is a process which can take several years and which is medically invasive and costly.”
This is a long process and takes time for women, which we will ensure is taken into account in the new language.
“The move follows a similar decision made by the US to change its gender recognition to reflect women’s experiences in the healthcare sector.
A Government spokesperson said: “The Gender Rights Act 2017 is designed to address gender inequity and to help ensure equality for all people in the public and private sectors.”
It is a national and international human rights act and covers a range of issues including discrimination and violence against women.”
Cancer is one of the most complex cancers and is an extremely challenging disease.
We want to ensure that the Government’s policy and action to help women and girls with cancer is aligned with this Act.
“The spokesman added that the Department of Health would continue to work closely with charities and the private sector on cancer and breast cancer treatment, with a view to supporting the development of new treatments.